Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
ECOG-ACRIN Cancer Research Group
With
National Cancer Institute (NCI)
OBJECTIVES:
Primary
* Genotype the full cohort of samples available from the RESORT clinical trial (ECOG-E4402) for FCGR3A 158V/F in parallel to independently verify results.
* Correlate the FCGR3A 158V/F polymorphisms to response, response duration, and time to rituximab resistance.
Secondary
* Quantify copy number variation in FCGR3A in this cohort.
OUTLINE: Archived DNA samples isolate from peripheral blood mononuclear cells and from formalin-fixed paraffin-embedded tissue samples are analyzed for FCGR3A 158V/F polymorphisms using different complementary genotyping methods. Assay results are reviewed and compared with patients' outcome data.
Age
18–120
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
DISEASE CHARACTERISTICS:
Diagnosed with indolent follicular lymphoma
Treated on RESORT trial (ECOG-E4402) comprising rituximab monotherapy and then randomized to rituximab maintenance therapy or retreatment with rituximab upon disease relapse
* Blood and tissue samples from patients available